A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-07-12
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 27); relationship: Y
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 29); relationship: not assessed
Grade 1 Dyspnoea — outcome: UNKNOWN; onset 2022-10-16 (study day 82); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 130); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 131); relationship: not assessed
Data queries
No data queries.